MIST Therapy® System Enters New Market within Wound Care

   Celleration, Inc., a Minneapolis-based medical device company,is expanding its patented MIST Therapy® System, an advanced wound care modality, to acute and home health care settings. The company’s primary commercialization focus for its innovative ultrasonic wound treatment device had been the product’s ability to treat chronic and hard-to-heal wounds in the outpatient and extended care markets. But because the technology has shown consistent clinical improvements and economic savings in capitated settings, physicians are interested in accessing the technology in acute care settings where at-risk wounds often can dehisce, as well as in home health care settings where control of patient care plans is difficult.     “In January 2009, Celleration will advance more aggressively into the acute and home health care settings with added sales and clinical personnel,” said Kevin Nickels, CEO of Celleration. “We are being integrated into these markets quickly by the demand of our customers as they are experiencing faster healing rates when combining the MIST Therapy® System with their current therapy protocols. They like the painless healing that MIST provides, and we believe this is a great opportunity to work alongside our physicians and clinicians. Our commitment to faster wound healing builds on the company’s history of creating real value to the healthcare industry.”

   Nickels also explained that payors need to adopt innovative technologies that provide clinically robust results across all care delivery settings, reduce the patient’s episodes of care, and save costs for the healthcare system. Adding the MIST system to current wound management practices will speed healing and ultimately save the healthcare system money by minimizing patient readmissions into higher cost facilities.

   To date, more than 750 MIST Therapy® Systems are currently being used in outpatient, acute, and long-term care facilities, as well as in skilled nursing homes across the United States. More than 15,000 patients have benefited. For more information, visit www.celleration.com.

Do you know a CEO of a wound, ostomy, or incontinence product manufacturing company that deserves to be spotlighted for groundbreaking industry news? Does he/she go above and beyond the call of duty? If so, please contact Chimere G. Holmes (cholmes@hmpcommunications.com) to nominate a deserving man or woman perpetuating the evolution of wound care.